Quantum Genomics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel peptide therapeutics that target key receptors in the renin–angiotensin system. By focusing on G-protein coupled receptor (GPCR) modulation within the brain, the company aims to address unmet needs in cardiovascular disease, with particular emphasis on resistant hypertension and related disorders.
The company’s lead product candidate, firibastat (formerly RB150), is a first-in-class peptide prodrug designed to inhibit aminopeptidase A and reduce central angiotensin II activity. Firibastat has advanced through Phase II clinical trials in patients with uncontrolled hypertension, demonstrating favorable safety and blood pressure-lowering effects. Quantum Genomics is also investigating additional indications for firibastat, including heart failure and metabolic complications associated with hypertension.
Founded in 2011 and headquartered in Paris, France, Quantum Genomics has built a research platform that integrates medicinal chemistry, peptide design and translational pharmacology. The company completed its initial public offering on Euronext Growth in 2018 and maintains an over-the-counter listing in the United States under the symbol QNNTF. Its development programs benefit from collaborations with academic research centers and contract research organizations across Europe and North America.
Quantum Genomics’ management team combines expertise in cardiovascular science, clinical development and regulatory affairs. Leveraging its deep understanding of the brain renin–angiotensin system, the company seeks to advance its pipeline through pivotal studies and pursue strategic partnerships to bring its first-in-class therapies to global markets.
AI Generated. May Contain Errors.
